A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
Phase of Trial: Phase II
Latest Information Update: 23 Jul 2017
At a glance
- Drugs Emapalumab (Primary)
- Indications Haemophagocytic lymphohistiocytosis
- Focus Adverse reactions
- Sponsors NovImmune SA
- 10 Jun 2017 Biomarkers information updated
- 19 Jan 2017 This trial was completed in Austria, according to European Clinical Trials Database.
- 15 Mar 2016 Planned number of patients changed from 10 to 35 as reported by ClinicalTrials.gov record.